349P - EXPLORE-LC: A multi-site real-world evidence research platform for non-small cell lung cancer in Asia-Pacific

Background

Lung cancer is the leading cause of cancer deaths in Asia-Pacific (APAC), with an estimated 1.1 million deaths in 2020. There is limited real-world evidence on the evolving landscape of molecular testing, treatment, and clinical outcomes among non-small cell lung cancer (NSCLC) patients in APAC using a standard approach across sites and markets. EXPLORE-LC is a multi-site research platform developed by lung cancer clinicians and IQVIA to facilitate high-quality NSCLC research.

Methods

Real-world data (RWD) from 5 sources in 3 APAC markets were extracted. Unstructured variables were derived or enhanced by the site. Data was transformed to a common data model and analysed with standardised R programming codes at each site. Aggregated statistical summaries of variables and analyses were shared to a central location and pooled using meta-analyses by IQVIA’s central team. Patients included had a NSCLC diagnosis, at least one treatment for NSCLC, and no history of concurrent primary cancer in the past 6 months. For all patients, data captured included characteristics, histology, biomarker status, and initial treatment. For advanced patients, additional information was gathered on treatment patterns, overall survival, and time to next treatment.

Results

EXPLORE-LC started at 4 institutions: Asan Medical Center; Samsung Medical Center; Severance Hospital, Yonsei in South Korea and Monash University Victorian Lung Cancer Registry in Australia. It includes 28,000 NSCLC patients diagnosed from January 2014 to December 2019, with follow-up until death, loss-to-follow-up, or March 2020. It was expanded to include Chang Gung Memorial Hospital, a 7-site hospital network in Taiwan with 7,000 NSCLC patients diagnosed from January 2016 to December 2020 and followed up until June 2021. 11,000 EGFR mutated, 2,800 ALK mutated, 90 RET mutated patients and 7,700 PD-L1 expressors were identified. Taiwan analyses ongoing and will be completed by Q4 2022.

Conclusions

The EXPLORE-LC network creates APAC’s first regional real-world research platform for NSCLC. This will enable detailed and rapid evidence generation on patient pathways and treatment trends and provide a robust platform for multi-source collaboration and insights into NSCLC in APAC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

IQVIA Solutions Asia Pte Ltd.

Funding

IQVIA Solutions Asia Pte Ltd.

Disclosure

K.C. Toh: Financial Interests, Institutional, Full or part-time Employment: IQVIA. X. Zhao, G. Stratton, H. Lin, K. Chou, D. Patel, N. Kleinman: Financial Interests, Personal, Full or part-time Employment: IQVIA. J.H. Kim: Financial Interests, Personal, Full or part-time Employment: IQVIA; Financial Interests, Personal, Invited Speaker: Sungkyunkwan university. D.H. Lee: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, ChongKeunDang, Janssen, MSD, Novartis, Ono, Pfizer, Roche, Samyang Biopharm, ST Cube, AbbVie, Takeda. S. Yoon: Financial Interests, Personal, Full or part-time Employment: Asan Medical Center. J.R. Zalcberg: Non-Financial Interests, Personal, Leadership Role: ICON Group; Financial Interests, Personal, Stocks/Shares: Biomarin, Opthea, Amarin Corporation, Concert Pharmaceuticals, Frequency Pharmaceuticals, Gilead Sciences, Madrigal Pharmaceuticals, UniQure, Zogenix, Ophazyme, Moderna Therapeutics, Twist Bioscience, Novavax; Financial Interests, Personal, Royalties: Specialised Therapeutics, Merck Serono, Targovax, Halozyme, Gilead Sciences, Deciphera; Financial Interests, Personal, Advisory Role: Merck Serono, Targovax, Merck Sharp & Dohme, Halozyme, Lipotek, Specialised Therapeutics, Center for Emerging & Neglected Diseases (CEND), Deciphera, Revolution Medicine, Fivephusion, Genor Biopharma, 1Globe Health Institute, Novotech, Merck Serono, Bristol Myers Squibb; Financial Interests, Institutional, Funding: AstraZeneca, Pfizer, IQVIA, Mylan, Ipsen, Eisai, Medtronic, MSD Oncology; Financial Interests, Personal, Other, travel, accommodations, expenses: Merck Serono, astrazeneca, Merck Sharp & Dohme, Deciphera, Sanofi. H.A. Jung: Financial Interests, Personal, Full or part-time Employment: Samsung Medical Center. S.M. Lim: Financial Interests, Personal, Funding: Yuhan, Janssen; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, Eli Lilly, Takeda, J Ints Bio; Financial Interests, Personal, Research Grant: Boehringer Ingelheim, AstraZeneca, GSK, Roche, Hengrui, Bridge Therapeutics, Oscotec. J.A. kim: Financial Interests, Personal, Full or part-time Employment: IQVIA; Financial Interests, Personal, Invited Speaker: KoNect, Korean academy of medical society. All other authors have declared no conflicts of interest.